We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
After years of uncontrolled spending, the UK’s troubled Cancer Drugs Fund has presented the National Health Service with a restructuring plan to get back on track. Read More
Six new drugs scored wins at the European Medicines Agency, scooping up recommendations for marketing authorization from the Committee for Medicinal Products for Human Use. Read More
The FDA has delivered PTC Therapeutics a stinging rebuke, sending the company a refuse to file letter for Translarna, its candidate for the treatment of nonsense mutation Duchenne muscular dystrophy. Read More
The response letter is for Merck’s sNDAs for cholesterol drugs Zetia and Vytorin to reduce the risk of cardiovascular events in patients with coronary heart disease. Read More